IL251200B - Aldosterone synthase inhibitors - Google Patents

Aldosterone synthase inhibitors

Info

Publication number
IL251200B
IL251200B IL251200A IL25120017A IL251200B IL 251200 B IL251200 B IL 251200B IL 251200 A IL251200 A IL 251200A IL 25120017 A IL25120017 A IL 25120017A IL 251200 B IL251200 B IL 251200B
Authority
IL
Israel
Prior art keywords
synthase inhibitors
aldosterone synthase
aldosterone
inhibitors
synthase
Prior art date
Application number
IL251200A
Other languages
English (en)
Hebrew (he)
Other versions
IL251200A0 (en
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54352516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL251200(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IL251200A0 publication Critical patent/IL251200A0/en
Publication of IL251200B publication Critical patent/IL251200B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL251200A 2014-10-15 2017-03-15 Aldosterone synthase inhibitors IL251200B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462064234P 2014-10-15 2014-10-15
PCT/US2015/055421 WO2016061161A1 (en) 2014-10-15 2015-10-14 Aldosterone synthase inhibitors

Publications (2)

Publication Number Publication Date
IL251200A0 IL251200A0 (en) 2017-05-29
IL251200B true IL251200B (en) 2019-05-30

Family

ID=54352516

Family Applications (1)

Application Number Title Priority Date Filing Date
IL251200A IL251200B (en) 2014-10-15 2017-03-15 Aldosterone synthase inhibitors

Country Status (33)

Country Link
US (1) US9745289B2 (enExample)
EP (1) EP3207039B1 (enExample)
JP (1) JP6279812B2 (enExample)
KR (1) KR102441634B1 (enExample)
CN (1) CN107108587B (enExample)
AP (1) AP2017009829A0 (enExample)
AR (1) AR102266A1 (enExample)
AU (1) AU2015333611B2 (enExample)
CA (1) CA2964754C (enExample)
CL (1) CL2017000827A1 (enExample)
CO (1) CO2017003305A2 (enExample)
CY (1) CY1121650T1 (enExample)
DK (1) DK3207039T3 (enExample)
EA (1) EA031766B1 (enExample)
ES (1) ES2724555T3 (enExample)
HR (1) HRP20190896T1 (enExample)
HU (1) HUE043783T2 (enExample)
IL (1) IL251200B (enExample)
LT (1) LT3207039T (enExample)
ME (1) ME03381B (enExample)
MX (1) MX369025B (enExample)
NZ (1) NZ729688A (enExample)
PE (1) PE20170696A1 (enExample)
PH (1) PH12017500595B1 (enExample)
PL (1) PL3207039T3 (enExample)
PT (1) PT3207039T (enExample)
RS (1) RS58651B1 (enExample)
SG (1) SG11201701850UA (enExample)
SI (1) SI3207039T1 (enExample)
TR (1) TR201907755T4 (enExample)
TW (1) TWI731842B (enExample)
UA (1) UA118717C2 (enExample)
WO (1) WO2016061161A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9890171B2 (en) * 2014-12-02 2018-02-13 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
EP3562487B1 (en) * 2016-12-29 2023-11-29 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
JP7530384B2 (ja) 2019-05-01 2024-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング （ｒ）－（２－メチルオキシラン－２－イル）メチル ４－ブロモベンゼンスルホネート
CN116438200A (zh) 2020-09-10 2023-07-14 普雷西里克斯公司 针对fap的抗体片段
TW202339719A (zh) 2021-12-14 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療慢性腎臟病之醛固酮合成酶抑制劑
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
JP2025517625A (ja) 2022-05-02 2025-06-10 プレシリックス・ナームローゼ・ベンノートシヤープ プレターゲティング
CN121181527A (zh) * 2024-06-21 2025-12-23 江苏豪森药业集团有限公司 双稠环类化合物、及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201026688A (en) * 2008-10-07 2010-07-16 Schering Corp Benzodioxan analogues as alpha2C adrenergic receptor modulators
JP5659224B2 (ja) * 2009-05-15 2015-01-28 ノバルティス アーゲー アルドステロンシンターゼ阻害剤としてのアリールピリジン
AR088989A1 (es) * 2011-11-30 2014-07-23 Hoffmann La Roche Derivados biciclicos de dihidroisoquinolin-1-ona
JP6496246B2 (ja) * 2012-10-05 2019-04-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． アルドステロンシンターゼインヒビター関連用途としてのインドリン化合物
BR112015019836A2 (pt) * 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
JP6067181B2 (ja) * 2013-04-30 2017-01-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルドステロンシンターゼ阻害薬
HUE039981T2 (hu) * 2014-07-24 2019-02-28 Boehringer Ingelheim Int Aldoszteron szintáz inhibitorok

Also Published As

Publication number Publication date
CO2017003305A2 (es) 2017-07-19
HRP20190896T1 (hr) 2019-07-12
PE20170696A1 (es) 2017-06-07
JP6279812B2 (ja) 2018-02-14
CN107108587A (zh) 2017-08-29
LT3207039T (lt) 2019-05-10
KR102441634B1 (ko) 2022-09-13
EA031766B1 (ru) 2019-02-28
AU2015333611B2 (en) 2020-02-06
ME03381B (me) 2020-01-20
MX2017004852A (es) 2017-06-22
AR102266A1 (es) 2017-02-15
AP2017009829A0 (en) 2017-03-31
RS58651B1 (sr) 2019-05-31
EP3207039B1 (en) 2019-03-06
UA118717C2 (uk) 2019-02-25
MX369025B (es) 2019-10-25
SG11201701850UA (en) 2017-04-27
TWI731842B (zh) 2021-07-01
WO2016061161A1 (en) 2016-04-21
JP2017531016A (ja) 2017-10-19
US9745289B2 (en) 2017-08-29
CL2017000827A1 (es) 2017-11-03
PH12017500595B1 (en) 2020-11-25
SI3207039T1 (sl) 2019-05-31
PL3207039T3 (pl) 2019-08-30
KR20170066651A (ko) 2017-06-14
PH12017500595A1 (en) 2017-08-30
TW201629048A (zh) 2016-08-16
CN107108587B (zh) 2020-05-22
EA201790830A1 (ru) 2017-09-29
BR112017005859A2 (pt) 2017-12-26
IL251200A0 (en) 2017-05-29
NZ729688A (en) 2020-05-29
CY1121650T1 (el) 2020-07-31
CA2964754A1 (en) 2016-04-21
AU2015333611A1 (en) 2017-03-23
DK3207039T3 (en) 2019-04-23
ES2724555T3 (es) 2019-09-12
HUE043783T2 (hu) 2019-09-30
PT3207039T (pt) 2019-06-04
CA2964754C (en) 2023-01-24
US20160108026A1 (en) 2016-04-21
EP3207039A1 (en) 2017-08-23
TR201907755T4 (tr) 2019-06-21

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
ZA201701846B (en) Spirodiamine derivatives as aldosterone synthase inhibitors
GB201421083D0 (en) Enzyme inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
GB201421088D0 (en) New enzyme inhibitors
EP3116503A4 (en) Hptp-beta inhibitors
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
GB201421085D0 (en) New enzyme inhibitors
IL246400A0 (en) Neprilysin inhibitors
IL249665B (en) Aldosterone synthase inhibitors
IL251200B (en) Aldosterone synthase inhibitors
GB201400299D0 (en) Corrosion inhibitors
ZA201903149B (en) Aldosterone synthase inhibitor
IL249234A0 (en) Osteoclast inhibitors for pain management
EP3180003A4 (en) Pkc-epsilon inhibitors
GB201418154D0 (en) Inhibitors
HK1239455A1 (zh) Smyd抑制剂
GB201400300D0 (en) Corrosion inhibitors
AU2014900536A0 (en) Inhibitors
AU2014900535A0 (en) Inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed